Switching HIV treatment: 2-drug versus 3-drug plan
Part of Infections clinical trials.
This trial compares two different HIV treatment plans: keeping you on a 2-drug regimen versus switching to a 3-drug regimen. It’s designed for people whose HIV is well controlled and looks at whether the switch is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and able to sign written consent
- Be able to come to all required clinic visits and complete the study steps
- Have HIV virus levels below 50 copies/mL for at least 3 months on an integrase-based medicine (a “2nd generation INSTI” regimen)
- Be able to provide blood samples, including samples stored long-term for future research
- Use reliable birth control if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects data from HIV patients who start treatment with a two-drug combination of dolutegravir and lamivudine, either as their first treatment or after switching from a three-drug regimen.
This study follows people with HIV whose virus is well-controlled on current medications to understand how switching to a different HIV drug regimen affects the virus's ability to resist those drugs. The goal is to help doctors choose the safest treatment switches.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.